Bell KJDel Mar CWright G. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer 2015;137:1749–1757.
Roach M IIIThomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States Preventive Task Force report on screening? J Natl Cancer Inst Monogr 2012;2012:221–229.
- Search Google Scholar
- Export Citation
)| false . , Roach M III Thomas K Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States Preventive Task Force report on screening? 2012; 2012: 221– 229. 10.1093/jncimonographs/lgs039
Schröder FHHugosson JRoobol MJ. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–2035.
- Search Google Scholar
- Export Citation
)| false . , Schröder FH , Hugosson J , Roobol MJ Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. 2014; 384: 2027– 2035. 25108889 10.1016/S0140-6736(14)60525-0
van Leeuwen PJKranse RHakulinen T. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen 2013;20:33–38.
Andriole GLCrawford EDGrubb RL. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Pinsky PFProrok PCYu K. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123:592–599.
Martin RMDonovan JLTurner EL. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 2018;319:883–895.
Stanford JLFeng ZHamilton AS. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354–360.
Wilt TJMacDonald RRutks I. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435–448.
Wilt TJBrawer MKJones KM. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–213.
Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.
Lin KLipsitz RMiller T. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192–199.
Bill-Axelson AHolmberg LGarmo H. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Brooks JD. Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer 2013;119:3906–3909.
Barbosa PVThomas ICSrinivas S. Overall survival in patients with localized prostate cancer in the US Veterans Health Administration: is PIVOT generalizable? Eur Urol 2016;70:227–230.
Weiner ABPatel SGEtzioni R. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 2015;193:95–102.
Grossman DCCurry SJOwens DK. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1901–1913.
Borza TKaufman SRShahinian VB. Sharp decline in prostate cancer treatment among men in the general population, but not among diagnosed men. Health Aff (Millwood) 2017;36:108–115.
Jemal AFedewa SAMa J. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054–2061.
Negoita SFeuer EJMariotto A. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer 2018;124:2801–2814.
Hutchinson RAkhtar AHaridas J. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. Cancer 2016;122:3785–3793.
Dimick JBRyan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA 2014;312:2401–2402.
Ryan AMBurgess JF JrDimick JB. Why we should not be indifferent to specification choices for difference-in-differences. Health Serv Res 2015;50:1211–1235.
Seneviratne MGSeto TBlayney DW. Architecture and implementation of a clinical research data warehouse for prostate cancer. EGEMS (Wash DC) 2018;6:13.
Wallace PJShah NDDennen T. Optum Laboratories: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187–1194.
Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975-2015) National Cancer Institute DCCPS Surveillance Research Program released April 2018 based on the November 2017 submission.
Fleshner KCarlsson SVRoobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 2017;14:26–37.
Drazer MWHuo DEggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416–2423.
Sammon JDAbdollah FChoueiri TK. Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015;314:2077–2079.
Kim SPKarnes RJGross CP. Contemporary national trends of prostate cancer screening among privately insured men in the United States. Urology 2016;97:111–117.
Gandaglia GBriganti AFossati N. The problem is not what to do with indolent and harmless prostate cancer—the problem is how to avoid finding these cancers. Eur Urol 2016;70:547–548.
Polascik TJPassoni NMVillers A. Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 2014;20:6254–6257.
Jemal AMa JSiegel R. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2016;2:1657–1660.
Potosky ALLegler JAlbertsen PC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582–1592.
Hamdy FCDonovan JLLane JA. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–1424.